Shan Liang, Wang Fengling, Zhai Dandan, Meng Xiangyun, Liu Jianjun, Lv Xiongwen
Department of Pharmacy, The Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, China.
Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, Hefei, China.
Front Pharmacol. 2022 Jun 13;13:874408. doi: 10.3389/fphar.2022.874408. eCollection 2022.
The morbidity and mortality of hepatic fibrosis caused by various etiologies are high worldwide, and the trend is increasing annually. At present, there is no effective method to cure hepatic fibrosis except liver transplantation, and its serious complications threaten the health of patients and cause serious medical burdens. Additionally, there is no specific drug for the treatment of hepatic fibrosis, and many drugs with anti-hepatic fibrosis effects are in the research and development stage. Recently, remarkable progress has been made in the research and development of anti-hepatic fibrosis drugs targeting different targets. We searched websites such as PubMed, ScienceDirect, and Home-ClinicalTrials.gov and found approximately 120 drugs with anti-fibrosis properties, some of which are in phase Ⅱ or Ⅲ clinical trials. Additionally, although these drugs are effective against hepatic fibrosis in animal models, most clinical trials have shown poor results, mainly because animal models do not capture the complexity of human hepatic fibrosis. Besides, the effect of natural products on hepatic fibrosis has not been widely recognized at home and abroad. Furthermore, drugs targeting a single anti-hepatic fibrosis target are prone to adverse reactions. Therefore, currently, the treatment of hepatic fibrosis requires a combination of drugs that target multiple targets. Ten new drugs with potential for development against hepatic fibrosis were selected and highlighted in this mini-review, which provides a reference for clinical drug use.
在全球范围内，各种病因引起的肝纤维化的发病率和死亡率都很高，且呈逐年上升趋势。目前，除肝移植外，尚无有效的方法治愈肝纤维化，其严重并发症威胁着患者的健康并造成沉重的医疗负担。此外，尚无治疗肝纤维化的特效药物，许多具有抗肝纤维化作用的药物正处于研发阶段。近年来，针对不同靶点的抗肝纤维化药物研发取得了显著进展。我们检索了PubMed、ScienceDirect和Home-ClinicalTrials.gov等网站，发现约有120种具有抗纤维化特性的药物，其中一些正处于Ⅱ期或Ⅲ期临床试验阶段。此外，尽管这些药物在动物模型中对肝纤维化有效，但大多数临床试验结果不佳，主要原因是动物模型无法体现人类肝纤维化的复杂性。此外，天然产物对肝纤维化的作用在国内外尚未得到广泛认可。此外，针对单一抗肝纤维化靶点的药物容易出现不良反应。因此，目前肝纤维化的治疗需要联合使用针对多个靶点的药物。本综述精选并重点介绍了10种具有抗肝纤维化开发潜力的新药，为临床用药提供参考。
